T1D, Metabolic Syndrome and Insulin Resistance

Clinical Characteristics in Adults With Type 1 Diabetes, Metabolic Syndrome and Insulin Resistance

Patients with type 1 diabetes (T1D) and metabolic syndrome (MS) require high doses of insulin to achieve a glycemic control, due to insulin resistance (IR). The investigators identified the presence of metabolic syndrome and insulin resistance in patients with T1D in a population of southeast Mexico.

The sampled population was recruited from the Diabetes Clinic of the Regional Hospital of High Specialty "Dr. Gustavo A. Rovirosa Pérez"; from August 2021 to February 2022, graduated physicians interviewed patients previously diagnosed with T1D. This study included patients older than 18 years and at least six months after being diagnosed with T1D. The interviewers excluded patients who did not attend regular consultations and those who did not agree to participate or to give a blood sample. A diabetologist evaluated and diagnosed all patients based on the World Health Organization (WHO) criteria.

Fasting glucose, total cholesterol, HDL cholesterol, LDL cholesterol, and triacylglycerols were determined in blood serum using a Clinical Chemistry System from Random Access Diagnostics. The reasearch team determined glycated hemoglobin concentrations by an enzymatic immunoassay method.

Study Overview

• Status: Completed
• Conditions: Metabolic Syndrome; Insulin Resistance; Type 1 Diabetes

• Study Type: Observational
• Enrollment (Actual): 19

Contacts and Locations

Study Locations

• Mexico
  • Tabasco
    • Villahermosa, Tabasco, Mexico, 86090
      • Isela Esther Juarez Rojop

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 50 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients who attend Diabetes Clinic of the Regional Hospital of High Specialty "Dr. Gustavo A. Rovirosa Pérez", previously diagnosed with type 1 diabetes

Description

Inclusion Criteria:

• At least six months after being diagnosed with T1D

Exclusion Criteria:

• Did not attend regular consultations
• Did not agree to participate or to give a blood sample

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Glycated hemoglobin	Concentrations by an enzymatic immunoassay method	March 2022
Total cholesterol, HDL cholesterol, LDL cholesterol, and triacylglycerols	Determined in blood serum using a Clinical Chemistry System from Random Access Diagnostics	March 2022

Collaborators and Investigators

• Sponsor: Universidad Juárez Autónoma de Tabasco

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2021
• Primary Completion (Actual): February 15, 2022
• Study Completion (Actual): March 1, 2022

Study Registration Dates

• First Submitted: August 13, 2022
• First Submitted That Met QC Criteria: August 13, 2022
• First Posted (Actual): August 16, 2022

Study Record Updates

• Last Update Posted (Actual): August 19, 2022
• Last Update Submitted That Met QC Criteria: August 16, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Glucose Metabolism Disorders; Metabolic Diseases; Immune System Diseases; Autoimmune Diseases; Endocrine System Diseases; Disease; Diabetes Mellitus; Hyperinsulinism; Syndrome; Diabetes Mellitus, Type 1; Metabolic Syndrome; Insulin Resistance
• Other Study ID Numbers: T1D-DACS2022

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No